Kun Zhou

Kun Zhou

Auto-generated profile, based on publicly available information

Kun Zhou

Luye Pharma Boston R&D, Woburn, Massachusetts

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KZKun Zhou
Kun Zhou
JCJae Eun Cheong
Jae Eun Cheong
SKSubrahmanian Tarakkad Krishnaji
Subrahmanian Tarakkad Krishnaji
AGAram Ghalali
Aram Ghalali
HFHaojie Fu
Haojie Fu
BZBruce R. Zetter
Bruce R. Zetter
We have synthesized an oxetane derivative of the benzimidazole compound mebendazole (OBD9) with enhanced solubility and strong anticancer activity in multiple types of cancer cells, especially colorectal cancer. In this report, we provide evidence that OBD9 suppresses colorectal cancer growth by interfering with the Wnt signaling pathway, a main driver of cell growth in colorectal cancer. Specifically, we find that OBD9 induces autophagic degradation of TNIK (traf2 and Nck-interacting kinase), which promotes T-cell factor-4 (TCF4)/beta-catenin–mediated gene expression. Thus, OBD9 as a TNIK inhibitor blocks Wnt/beta-catenin signaling at the final step of transcriptional activation. We suggest that OBD9 provides a potential novel autophagy-mediated, Wnt-damping therapeutic strategy for the treatment of colorectal cancer.

10 March 2010 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
KZKun Zhou
Kun Zhou
LHLifang Huang
Lifang Huang
ZZZhi-Gang Zhou
Zhi-Gang Zhou
CHCaihong Hu
Caihong Hu
WLWenli Liu
Wenli Liu
HSHanying Sun
Hanying Sun

16 August 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
TYTianchi Yu
Tianchi Yu
WTWang Tao
Wang Tao
SKShifang Kuang
Shifang Kuang
GZGuoping Zhao
Guoping Zhao
KZKun Zhou
Kun Zhou
HZHui Zhang
Hui Zhang
Vascular smooth muscle cells (VSMCs) serve a decisive role in intimal hyperplasia, a common pathophysiological process that leads to numerous vascular disorders. The present study aimed to investigate the unknown mechanisms underlying VSMC phenotypic modulation and identified a novel microRNA (miRNA/miR)‑17‑5p/homeobox B13 (HOXB13) axis involved in the phenotypic switching, proliferation and migration of VSMCs. VSMCs were isolated from the thoracic aorta of Sprague‑Dawley rats, cell proliferation was determined by Cell Counting Kit‑8 (CCK‑8) assay, cell migration was examined by Transwell migration assay and gene expression was detected using reverse transcription‑quantitative PCR and western blot analyses. It was firstly found that incubation with platelet‑derived growth factor‑BB (PDGF‑BB) recombinant protein resulted in a significant increase in HOXB13 expression in VSMCs. Using multiple miRNA prediction tools, miR‑17‑5p was identified as a potential regulator for HOXB13, since it had a 7‑base perfect binding site and a 5‑base imperfect binding site with the 3'‑untranslated region of HOXB13 mRNA, and these sequences were highly conserved across species. The regulatory effect of miR‑17‑5p on HOXB13 was validated using luciferase reporter assays. The expression level of miR‑17‑5p was increased in VSMCs under PDGF‑BB stimulation, and was negatively correlated with HOXB13 mRNA and protein expression. Moreover, the miR‑17‑5p mimics significantly inhibited the proliferation and migration of VSMCs, while antagomiR‑17‑5p showed the opposite effects, which could be abolished by HOXB13 knockdown. The miR‑17‑5p/HOXB13 axis also regulated the expression levels of the markers of differentiated VSMCs (α‑smooth muscle actin, transgelin and smoothelin), proliferating cell nuclear antigen and cell migration proteins, including MMP‑2 and ‑9. In conclusion, the present study demonstrated that miR‑17‑5p inhibited the phenotypic modulation VSMCs stimulated by PDGF‑BB by downregulating HOXB13, indicating that these factors may be potential therapeutic targets for intimal hyperplasia.

3 April 2023
Verified
Other
Open access
KZKun Zhou
Kun Zhou
JCJae Eun Cheong
Jae Eun Cheong
SKSubrahmanian Tarakkad Krishnaji
Subrahmanian Tarakkad Krishnaji
AGAram Ghalali
Aram Ghalali
HFHaojie Fu
Haojie Fu
BZBruce Zetter
Bruce Zetter
Supplementary figures and table

3 April 2023
Verified
Other
Open access
KZKun Zhou
Kun Zhou
JCJae Eun Cheong
Jae Eun Cheong
SKSubrahmanian Tarakkad Krishnaji
Subrahmanian Tarakkad Krishnaji
AGAram Ghalali
Aram Ghalali
HFHaojie Fu
Haojie Fu
BZBruce Zetter
Bruce Zetter
Supplementary figures and table

27 November 2025
Verified
Other
Open access
KZKun Zhou
Kun Zhou
JCJae Eun Cheong
Jae Eun Cheong
SKSubrahmanian Tarakkad Krishnaji
Subrahmanian Tarakkad Krishnaji
AGAram Ghalali
Aram Ghalali
HFHaojie Fu
Haojie Fu
BZBruce Zetter
Bruce Zetter
We have synthesized an oxetane derivative of the benzimidazole compound mebendazole (OBD9) with enhanced solubility and strong anticancer activity in multiple types of cancer cells, especially colorectal cancer. In this report, we provide evidence that OBD9 suppresses colorectal cancer growth by interfering with the Wnt signaling pathway, a main driver of cell growth in colorectal cancer. Specifically, we find that OBD9 induces autophagic degradation of TNIK (traf2 and Nck-interacting kinase), which promotes T-cell factor-4 (TCF4)/beta-catenin–mediated gene expression. Thus, OBD9 as a TNIK inhibitor blocks Wnt/beta-catenin signaling at the final step of transcriptional activation. We suggest that OBD9 provides a potential novel autophagy-mediated, Wnt-damping therapeutic strategy for the treatment of colorectal cancer.